Your browser is no longer supported. Please, upgrade your browser.
Innoviva, Inc.
Index- P/E6.56 EPS (ttm)1.94 Insider Own31.97% Shs Outstand101.36M Perf Week-1.17%
Market Cap1.28B Forward P/E8.42 EPS next Y1.51 Insider Trans0.00% Shs Float68.98M Perf Month7.75%
Income216.40M PEG0.34 EPS next Q0.41 Inst Own76.10% Short Float13.57% Perf Quarter27.33%
Sales322.30M P/S3.98 EPS this Y-60.20% Inst Trans-0.77% Short Ratio13.01 Perf Half Y-12.22%
Book/sh4.79 P/B2.66 EPS next Y-12.21% ROA26.10% Target Price10.00 Perf Year-12.34%
Cash/sh4.75 P/C2.68 EPS next 5Y19.34% ROE52.90% 52W Range7.58 - 15.62 Perf YTD2.66%
Dividend- P/FCF- EPS past 5Y32.70% ROI29.60% 52W High-18.57% Beta0.63
Dividend %- Quick Ratio146.80 Sales past 5Y98.70% Gross Margin- 52W Low67.81% ATR0.41
Employees5 Current Ratio146.80 Sales Q/Q34.80% Oper. Margin96.20% RSI (14)61.39 Volatility3.81% 3.10%
OptionableYes Debt/Eq0.79 EPS Q/Q-26.30% Profit Margin67.20% Rel Volume0.57 Prev Close12.87
ShortableYes LT Debt/Eq0.79 Earnings- Payout0.00% Avg Volume719.64K Price12.72
Recom4.00 SMA202.70% SMA5011.82% SMA2002.83% Volume412,338 Change-1.17%
Nov-20-17Initiated Deutsche Bank Hold $13
Jan-05-21 10:37AM  
Jan-04-21 10:11AM  
Jan-01-21 11:50AM  
Dec-29-20 01:09PM  
Dec-28-20 11:38AM  
Dec-24-20 09:21AM  
Dec-18-20 09:30PM  
Dec-16-20 11:50AM  
Dec-10-20 08:42AM  
Dec-09-20 04:02PM  
Dec-07-20 10:07AM  
Dec-03-20 11:17AM  
Dec-02-20 07:48AM  
Dec-01-20 08:29AM  
Nov-30-20 11:50AM  
Nov-27-20 08:29AM  
Nov-24-20 09:08AM  
Nov-19-20 08:20AM  
Nov-17-20 08:23AM  
Nov-02-20 10:23AM  
Oct-28-20 04:30PM  
Oct-13-20 03:28PM  
Oct-12-20 10:19AM  
Sep-25-20 07:09AM  
Sep-10-20 11:06AM  
Sep-09-20 06:45PM  
Sep-03-20 08:30AM  
Aug-28-20 08:00AM  
Aug-24-20 11:35AM  
Aug-04-20 11:33AM  
Jul-29-20 04:05PM  
Jul-27-20 02:32PM  
Jul-20-20 11:17AM  
Jul-06-20 12:58PM  
Jun-23-20 08:34PM  
Jun-11-20 04:05PM  
Jun-09-20 05:50PM  
Jun-08-20 11:50AM  
Jun-03-20 05:50PM  
May-28-20 05:50PM  
May-26-20 09:05AM  
May-21-20 04:05PM  
May-19-20 11:30AM  
May-10-20 03:19PM  
May-07-20 04:05PM  
May-06-20 10:03AM  
May-05-20 11:50AM  
May-01-20 11:30AM  
Apr-29-20 04:05PM  
Apr-28-20 11:58AM  
Apr-23-20 11:37AM  
Apr-22-20 04:05PM  
Apr-19-20 09:11AM  
Apr-16-20 11:50AM  
Apr-07-20 09:47AM  
Mar-31-20 04:05PM  
Mar-30-20 07:30AM  
Mar-20-20 07:03AM  
Mar-09-20 01:30PM  
Mar-06-20 09:02AM  
Feb-27-20 09:36AM  
Feb-25-20 09:05AM  
Feb-12-20 08:02AM  
Feb-04-20 10:19AM  
Jan-28-20 07:00AM  
Jan-13-20 05:21PM  
Jan-08-20 05:50PM  
Jan-07-20 08:43AM  
Dec-31-19 11:05AM  
Dec-30-19 05:17PM  
Dec-27-19 05:50PM  
Dec-26-19 09:55AM  
Dec-24-19 09:16AM  
Dec-20-19 09:28AM  
Dec-19-19 10:02AM  
Dec-18-19 05:45PM  
Dec-17-19 11:50AM  
Dec-16-19 09:46AM  
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Innoviva, Inc.10% OwnerMar 27Buy2.877,717,66122,149,6878,710,800Mar 31 04:54 PM
Zhen MarianneChief Accounting OfficerFeb 24Sale14.782,95443,66021,913Feb 24 04:40 PM